Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; and CAP-2003, and allogeneic cardiosphere-derived cells-exosomes, which is in preclinical trial to treat DMD. It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.

Capricor Therapeutics Inc.

Capricor Therapeutics, Inc. (($CAPR)) has held its Q4 earnings call. Read on for the main highlights of the call. Capricor Therapeutics’ latest ear...

Capricor Therapeutics Nears Key Milestones After Earnings Call

Alliance Global Partners analyst reiterated a Buy rating on Capricor Therapeutics today and set a price target of $51.00. In a report released toda...

Alliance Global Partners Keeps Their Buy Rating on Capricor Therapeutics (CAPR)

In a report released today, Leland Gershell from Oppenheimer reiterated a Buy rating on Capricor Therapeutics, with a price target of $54.00. Accor...

Oppenheimer Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)

Capricor Therapeutics ( ($CAPR) ) has shared an update. On March 10, 2026, Capricor Therapeutics said the U.S. Food and Drug Administration lifted ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CAPR	$31.35	-1.94%	433.43K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CAPR	$31.35	-1.9%	433.43K
3
4
5
6

CAPR

CAPR

Get Capricor Therapeutics Inc. Data in Excel

Get Capricor Therapeutics Inc. Data in Excel